September 2026
1. ELIAS KM, Mitchell A, Stadler E, Schlub TE, et al
   Neutralising antibodies and protection from progression to severe COVID-19: A meta-analysis.
   PLoS Med. 2026;23:e1005230.
   

   >> Share

   
   July 2026
2. KUMAR CK, Lo NC
   Re-emergence of vaccine-preventable diseases in the post-elimination era.
   PLoS Med. 2026;23:e1005175.
   

   >> Share

   
   June 2026
3. HAGAN JE
   The well-worn path from armed conflict to measles resurgence.
   PLoS Med. 2026;23:e1005156.
   

   >> Share

   
   May 2026
4. HYSA A, Opi DH, Waterhouse J, Chishimba S, et al
   Antibody fine specificity correlates with protection from malaria for the RTS,S vaccine in young African children: A post hoc analysis of a phase IIb randomised controlled trial.
   PLoS Med. 2026;23:e1004877.
   

   >> Share

   
   April 2026
5. WILDER-SMITH A
   Optimizing dengue vaccination strategies.
   PLoS Med. 2026;23:e1005068.
   

   >> Share

   
   March 2026
6. ABDEL-QADIR H, Bhatt HA, Swayze S, Paterson M, et al
   Association between COVID-19 vaccination and sudden death in apparently healthy younger individuals: A population-based case-control study.
   PLoS Med. 2026;23:e1004924.
   

   >> Share

   
   
7. GRAY EJ, Cooper LV, Gonzalez AR, Mach O, et al
   Estimating population immunity against serotype-two poliomyelitis from the inactivated polio vaccine in routine immunization across 112 countries: A modelling study.
   PLoS Med. 2026;23:e1004952.
   

   >> Share

   
   February 2026
8. TANVIR H, Clark RA, Sumner T, Horton KC, et al
   Estimating the population impact of new tuberculosis vaccines depending on efficacy against infectious asymptomatic tuberculosis: A modelling study.
   PLoS Med. 2026;23:e1004595.
   

   >> Share

   
   
9. CARVALHO N, Watts E, Oliver VL, Clark A, et al
   Evaluation of rotavirus, pneumococcal conjugate and human papillomavirus vaccination in four Pacific island countries: A cost-effectiveness modelling study.
   PLoS Med. 2026;23:e1004604.
   

   >> Share

   
   January 2026
10. STANTON TD, Keegan SP, Abdulahi JA, Amulele AV, et al
    Distribution of capsule and O types in Klebsiella pneumoniae causing neonatal sepsis in Africa and South Asia: A meta-analysis of genome-predicted serotype prevalence to inform potential vaccine coverage.
    PLoS Med. 2026;23:e1004879.
    

    >> Share

    
    
11. MONOI A, Endo A, Procter SR, Leuba SI, et al
    The benefits and risks of maternal RSV vaccination on mortality in South Africa: A modeling study.
    PLoS Med. 2026;23:e1004625.
    

    >> Share

    
    December 2025
12. GOTTLIEB SL, Rees H, Peters RPH
    Vaccines to prevent bacterial sexually transmitted infections: Promise, progress, and public health potential.
    PLoS Med. 2025;22:e1004849.
    

    >> Share

    
    November 2025
13. JIAO B, Sato R, Mak J, Patenaude B, et al
    Financial risk protection from vaccines in 52 Gavi-eligible low- and middle-income countries: A modeling study.
    PLoS Med. 2025;22:e1004764.
    

    >> Share

    
    October 2025
14. KAWAMOTO A, Hashida M, Ishida K, Furihata K, et al
    Immunogenicity and safety of DS-5670d, an omicron XBB.1.5-targeting COVID-19 mRNA vaccine: A phase 3, randomized, active-controlled study.
    PLoS Med. 2025;22:e1004499.
    

    >> Share

    
    
15. SHEN J, Kharitonova E, Tytula A, Zawieja J, et al
    Correction: Vaccination strategies, public health impact and cost-effectiveness of dengue vaccine TAK-003: A modeling case study in Thailand.
    PLoS Med. 2025;22:e1004789.
    

    >> Share

    
    September 2025
16. MANDOLO J, Mulira L, Moyo M, Mvula M, et al
    Maternal-infant rotavirus-specific antibody kinetics to inform timing of vaccine boosting in Malawi: An observational study.
    PLoS Med. 2025;22:e1004734.
    

    >> Share

    
    
17. JIN S, Asakura TR, Murayama H, Niyukuri D, et al
    Vaccination strategies to achieve outbreak control for MPXV Clade I with a one-time mass campaign in sub-Saharan Africa: A scenario-based modelling study.
    PLoS Med. 2025;22:e1004726.
    

    >> Share

    
    July 2025
18. LI J, Li Y, Qin C, He Y, et al
    Effect of a pay-it-forward strategy on reducing HPV vaccine delay and increasing uptake among 15- to 18-year-old girls in China: A randomized controlled trial.
    PLoS Med. 2025;22:e1004535.
    

    >> Share

    
    June 2025
19. GOODFELLOW L, Procter SR, Koltai M, Waterlow NR, et al
    The potential global health impact and cost-effectiveness of next-generation influenza vaccines: A modelling analysis.
    PLoS Med. 2025;22:e1004655.
    

    >> Share

    
    
20. SHEN J, Kharitonova E, Tytula A, Zawieja J, et al
    Vaccination strategies, public health impact and cost-effectiveness of dengue vaccine TAK-003: A modeling case study in Thailand.
    PLoS Med. 2025;22:e1004631.
    

    >> Share

    
    April 2025
21. 
    Correction: Contraception use and pregnancy in women receiving a 2-dose Ebola vaccine in Rwanda: A retrospective analysis of UMURINZI vaccination campaign data.
    PLoS Med. 2025;22:e1004605.
    

    >> Share

    
    February 2025
22. GENG L, Whittles LK, Dickens BL, Chio MTW, et al
    Potential public health impacts of gonorrhea vaccination programmes under declining incidences: A modeling study.
    PLoS Med. 2025;22:e1004521.
    

    >> Share

    
    
23. INGABIRE R, Nyombayire J, Mazzei A, Mazarati JB, et al
    Contraception use and pregnancy in women receiving a 2-dose Ebola vaccine in Rwanda: A retrospective analysis of UMURINZI vaccination campaign data.
    PLoS Med. 2025;22:e1004508.
    

    >> Share

    
    
24. GRAIS RF, Neuzil KM, Rees H, Toscano CM, et al
    Protecting mother and baby: Learnings from an Ebola vaccination campaign on the evolving landscape of vaccines and pregnancy.
    PLoS Med. 2025;22:e1004530.
    

    >> Share

    
    
25. GUTTIERES D, Diepvens C, Grais RF, Kiarie J, et al
    Charting a novel path towards Ebola virus disease preparedness: Considerations for preventive vaccination.
    PLoS Med. 2025;22:e1004543.
    

    >> Share

    
    January 2025
26. SEIDLEIN LV
    Roll out and prospects of the malaria vaccine R21/Matrix-M.
    PLoS Med. 2025;22:e1004515.
    

    >> Share

    
    
27. GENG L, Whittles LK, Dickens BL, Chio MTW, et al
    Correction: Potential public health impacts of gonorrhea vaccination programmes under declining incidences: A modeling study.
    PLoS Med. 2025;22:e1004573.
    

    >> Share

    
    October 2024
28. MUNDAY JD, Atkins KE, Klinkenberg D, Meurs M, et al
    Estimating the risk and spatial spread of measles in populations with high MMR uptake: Using school-household networks to understand the 2013 to 2014 outbreak in the Netherlands.
    PLoS Med. 2024;21:e1004466.
    

    >> Share

    
    September 2024
29. INIZAN C, Courtot A, Sturmach C, Griffon AF, et al
    Levels and functionality of Pacific Islanders' hybrid humoral immune response to BNT162b2 vaccination and delta/omicron infection: A cohort study in New Caledonia.
    PLoS Med. 2024;21:e1004397.
    

    >> Share

    
    June 2024
30. PEREZ CHACON G, Estcourt MJ, Totterdell J, Marsh JA, et al
    Immunogenicity, reactogenicity, and IgE-mediated immune responses of a mixed whole-cell and acellular pertussis vaccine schedule in Australian infants: A randomised, double-blind, noninferiority trial.
    PLoS Med. 2024;21:e1004414.
    

    >> Share

    
    
31. LEACH AJ, Wilson N, Arrowsmith B, Beissbarth J, et al
    Hearing loss in Australian First Nations children at 6-monthly assessments from age 12 to 36 months: Secondary outcomes from randomised controlled trials of novel pneumococcal conjugate vaccine schedules.
    PLoS Med. 2024;21:e1004375.
    

    >> Share

    
    April 2024
32. JUNG SM, Loo SL, Howerton E, Contamin L, et al
    Potential impact of annual vaccination with reformulated COVID-19 vaccines: Lessons from the US COVID-19 scenario modeling hub.
    PLoS Med. 2024;21:e1004387.
    

    >> Share

    
    March 2024
33. MOODIE Z, Andersen-Nissen E, Grunenberg N, Dintwe OB, et al
    Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial.
    PLoS Med. 2024;21:e1004360.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share